GSK: ranked 2nd in the 'Access to Medicine' Index

(CercleFinance.com) - GSK announces that it has been ranked second in the Access to Medicine Index (ATMI).


This independent report assesses 20 of the world's leading pharmaceutical companies on their progress in improving access to medicines in 113 low-income countries, targeting 81 priority diseases.

GSK also ranks among the top three companies in all ATMI categories, achieving first place in 'Product Delivery'.

GSK highlights several initiatives, such as the supply of 1.2 billion vaccines for the Gavi Alliance, HIV treatments accessible to 90% of patients in sub-Saharan Africa, and a £1 billion investment over 10 years in research into high-burden infectious diseases such as tuberculosis and malaria.

Copyright (c) 2024 CercleFinance.com. All rights reserved.